Being Tactical = Mo...
Health Care: Drugs
Insys Therapeutics Inc (NEOL: OTC)
$12.00 0.00 | 0.00%
02/09/12 - 02:18 PM ET
1.03K / 600.00
Vol / Avg. Vol:11.00 / 12.00
Open / Prev. Close:11.00 - 12.00
Today's Range:1.05 - 23.42
52 Wk Range:33.33%
Performance YTD:TheStreet Rating:
Portfolios with NEOL
- Portfolio NameUser Type
- UserGaHogDawg Portfolio 1
- User071107
- UserPescador_23
- Userwilfie steele Portfolio 1
- Userdasbooch Portfolio 1
- Userfed6 Beaten ups 7-7-07
- UserOne Dollar Stocks (US)
- Userrglynn@affinityinc.net Port...
- UserPANTERA GROUP 45
- UserI'll never get to Retiremen...
Latest NEOL Headlines from TheStreet
- Thursday's Health Winners & Losers 08.06.07 | 10:08 pm
- Thursday's Health Winners & Losers 06.20.07 | 01:06 am
- Monday's Health Winners & Losers 12.11.06 | 03:12 pm
- NeoPharm Drug Fails 12.11.06 | 11:12 am
- Today's Health Winners and Losers 05.01.06 | 02:05 pm
- Cramer's 'Mad Money Lightning Round': In TrustCo I Trust 01.24.06 | 07:01 pm
- Health Stocks in Motion 12.29.05 | 03:12 pm
- Options in Motion: Guidant 12.27.05 | 02:12 pm
- Health Stocks in Motion 12.27.05 | 02:12 pm
- NeoPharm Study Can Continue 12.27.05 | 08:12 am
Press Releases for NEOL
- INSYS Announces NDA PDUFA Date For Fentanyl SL Spray - Business Wire 05.20.11 | 12:05 pm
- Insys Announces NDA Acceptance Of Its Fentanyl SL Spray - Business Wire 05.11.11 | 04:05 pm
- Insys Therapeutics, Inc. Announces Submission Of NDA For Fentanyl SL Spray - Business Wire 03.07.11 | 04:03 pm
- Insys Therapeutics, Inc. Announces Conference Call And Corporate Update - Business Wire 02.14.11 | 12:02 pm
- Dr. Daniel Von Hoff Joins INSYS Therapeutics/NeoPharm As Chief Development Officer - Business Wire 01.06.11 | 01:01 pm
- NeoPharm, Inc. Completes Merger With Insys Therapeutics, Inc. - Business Wire 11.09.10 | 04:11 pm
- NeoPharm, Inc. Announces Merger With Insys Therapeutics, Inc. - Business Wire 10.29.10 | 05:10 pm
- NeoPharm, Inc. Announces Second Quarter 2010 Financial Results - Business Wire 08.26.10 | 08:08 am
- NeoPharm, Inc. Announces First Quarter 2010 Financial Results And Clinical Trial Update - Business Wire 06.11.10 | 08:06 am
- NeoPharm Announces FDA Grant Of Orphan Drug Designation For IL13-PE38QQR For The Treatment Of Idiopathic Pulmonary Fibrosis - Business Wire 05.17.10 | 08:05 am
Partner Headlines for NEOL
